CHICAGO — The ban on further sales of transvaginal mesh for pelvic organ prolapse (POP) imposed by the US Food and Drug Administration (FDA) last month has some people cheering, some saying that an ...
On Monday, Henry Garrard, chairman of the fee and cost committee, fired back at four law firms objecting to their share of an estimated $550 million in common benefit fees. Lead plaintiffs' attorneys ...
December 26, 2008 — Trocar-guided transvaginal mesh surgery for pelvic organ prolapse results in good clinical outcomes at 1 year, according to the results of a prospective, multicenter cohort study ...
WASHINGTON (CN) - As reports of serious complications continue to rise, the Food and Drug Administration has issued two orders to manufacturers to strengthen requirements for transvaginal surgical ...
Please provide your email address to receive an email when new articles are posted on . Transvaginal mesh was noninferior to native tissue repair in women with pelvic organ prolapse at 36 months, ...
(Reuters) - The U.S. Food and Drug Administration on Tuesday ordered makers of transvaginal surgical mesh implants to immediately stop their sale and distribution in the United States, the latest ...
The Food and Drug Administration is ordering companies that produce mesh devices for women suffering from pelvic organ prolapse to end the sales of those products immediately. The companies, "Boston ...
Johnson & Johnson, a global healthcare giant based in New Brunswick, New Jersey, lost a product liability lawsuit surrounding its transvaginal mesh implants manufactured by Ethicon, a subsidiary of ...
NEW YORK (Reuters) - Boston Scientific Corp’s back-to-back losses in the first two federal trials over its transvaginal mesh devices could drive up the cost of resolving thousands of similar lawsuits, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback